<p>Takeda Pharmaceutical Co. Ltd. announced changes to its executive leadership team and organizational structure effective April 1, 2026. Key updates include the formation of an International Business Unit overseeing all markets outside the U.S., led by Giles Platford, and the creation of new groups for Strategy &amp; Portfolio Development and a Transformation Office. Several new executive roles are being recruited, including heads for Plasma-Derived Therapies, Strategy &amp; Portfolio Development, Global Communications &amp; Governance, and Global Human Resources. Julie Kim is named CEO-elect, and other executive team appointments include Akiko Amakawa as CEO Chief of Staff, Awny Farajallah for Global Medical, Elaine Shannon for Global Supply &amp; Quality, and Natalie Furney for Global Legal, Ethics &amp; Compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Takeda Announces Executive Team Overhaul and New Leadership Roles